Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at lære om Vepdegestrant, når det gives med PF-07220060 til personer med avanceret eller metastatisk brystkræft.

3. september 2026 opdateret af: Pfizer

EN INTERVENTIONEL SIKKERHED OG EFFEKTIVITET FASE 1B/2, ÅBEN LABEL UNDERSØGELSE TIL UNDERSØGELSE AF TOLERABILITET, PK OG ANTITUMOR AKTIVITET HOS VEPDEGESTRANT (ARV-471/PF-07850327), EN ORAL COGETOLYSIS0, I 70-200 DELTAGERE I alderen 18 ÅR OG ÆLDRE MED ER+/HER2- AVANCERET ELLER METASTATISK BRYSTCANCER

The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that:

  • is hard to treat (advanced) and may have spread to other organs (metastatic).
  • is sensitive to hormonal therapy (it is called estrogen receptor positive).
  • is no longer responding to treatments taken before starting this study.

All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until:

  • their cancer is no longer responding, or
  • side effects become too severe. They will have visits at the study clinic about every 4 weeks.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

C4891026 is a prospective, open-label, multicenter, Phase 1b/2 study to evaluate the safety, antitumor activity, and pharmacokinetic (PK) of vepdegestrant in combination with PF-07220060 in the treatment of participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

71

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Belgien
    • Antwerpen
      • Edegem, Antwerpen, Belgien, 2650
        • Antwerp University Hospital
    • Bruxelles-capitale, Région de
      • Anderlecht, Bruxelles-capitale, Région de, Belgien, 1070
        • Institut Jules Bordet
    • Vlaams-brabant
      • Leuven, Vlaams-brabant, Belgien, 3000
        • UZ Leuven
    • West-vlaanderen
      • Kortrijk, West-vlaanderen, Belgien, 8500
        • AZ Groeninge Campus Kennedylaan
  • Canada
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Cancer Centre
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Research Institute
  • Forenede Stater
    • Arkansas
      • Fayetteville, Arkansas, Forenede Stater, 72703
        • Highlands Oncology
      • Rogers, Arkansas, Forenede Stater, 72758
        • Highlands Oncology
      • Springdale, Arkansas, Forenede Stater, 72762
        • Highlands Oncology Group
    • California
      • Irvine, California, Forenede Stater, 92618
        • Hoag Hospital Irvine
      • Irvine, California, Forenede Stater, 92618
        • Hoag Health Center Irvine
      • Newport Beach, California, Forenede Stater, 92663
        • Hoag Memorial Hospital Presbyterian
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford Cancer Center
      • Palo Alto, California, Forenede Stater, 94304
        • Clinical and Translational Research Unit (CTRU)
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford Cancer Institute - Clinical Trials Office
      • San Francisco, California, Forenede Stater, 94158
        • UCSF Medical Center at Mission Bay
    • Colorado
      • Fort Collins, Colorado, Forenede Stater, 80524
        • UCHealth Poudre Valley Hospital
      • Fort Collins, Colorado, Forenede Stater, 80528
        • UCHealth Harmony
      • Greeley, Colorado, Forenede Stater, 80634
        • UCHealth Greeley Hospital
      • Loveland, Colorado, Forenede Stater, 80538
        • UCHealth - Medical Center of the Rockies
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06511
        • Smilow Cancer Hospital Phase 1 Unit
      • New Haven, Connecticut, Forenede Stater, 06510
        • Smilow Cancer Hospital - Yale New Haven Health
      • New Haven, Connecticut, Forenede Stater, 06510
        • Yale - New Haven Hospital - Yale Cancer Center
      • Trumbull, Connecticut, Forenede Stater, 06611
        • Smilow Cancer Hospital - Trumbull
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49546
        • START Midwest
    • New Jersey
      • Basking Ridge, New Jersey, Forenede Stater, 07920
        • MSK Basking Ridge
      • Middletown, New Jersey, Forenede Stater, 07748
        • MSK Monmouth
      • Montvale, New Jersey, Forenede Stater, 07645
        • MSK Bergen
    • New York
      • Commack, New York, Forenede Stater, 11725
        • MSK Commack
      • Harrison, New York, Forenede Stater, 10604
        • MSK Westchester
      • New York, New York, Forenede Stater, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Forenede Stater, 10022
        • Rockefeller Outpatient Pavilion (53rd Street)
      • New York, New York, Forenede Stater, 10065
        • Evelyn H. Lauder Breast and Imaging Center (BAIC).
      • Uniondale, New York, Forenede Stater, 11553
        • MSK Nassau
    • Texas
      • San Antonio, Texas, Forenede Stater, 78229
        • START San Antonio
    • Utah
      • Farmington, Utah, Forenede Stater, 84025
        • University of Utah, Farmington Health Center
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Huntsman Cancer Institute
      • Salt Lake City, Utah, Forenede Stater, 84106
        • University of Utah, Sugar House Health Center
      • South Jordan, Utah, Forenede Stater, 84106
        • South Jordan Health Center - University of Utah
      • West Valley City, Utah, Forenede Stater, 84119
        • START Mountain Region
  • Frankrig
    • Hérault
      • Montpellier, Hérault, Frankrig, 34298
        • Institut Régional du Cancer Montpellier
    • Loire-atlantique
      • Saint-Herblain, Loire-atlantique, Frankrig, 44805
        • Institut de Cancérologie de l'Ouest
    • Provence-Alpes-Côte d'Azur Region
      • Marseille, Provence-Alpes-Côte d'Azur Region, Frankrig, 13273
        • Institut Paoli-Calmettes
  • Japan
      • Tokyo, Japan, 142-8666
        • Showa Medical University Hospital
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • National Cancer Center Hospital East
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2418515
        • Kanagawa cancer center
    • Tokyo
      • Chuo-ku, Tokyo, Japan, 104-0045
        • National Cancer Center Hospital
  • Kina
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510060
        • Sun Yat-sen University Cancer Center
    • Hubei
      • Wuhan, Hubei, Kina, 430023
        • Wuhan Union Hospital Cancer Center
    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
  • Puerto Rico
      • Mayagüez, Puerto Rico, 00680
        • BRCR Global - Mayaguez Administrative Office
      • Mayagüez, Puerto Rico, 00682
        • BRCR Global - Mayagüez
      • Rio Piedras, Puerto Rico, 00935
        • Pan American Center for Oncology Trials, LLC
  • Spanien
      • Seville, Spanien, 41013
        • Hospital Universitario Virgen Del Rocio
    • Barcelona [barcelona]
      • Barcelona, Barcelona [barcelona], Spanien, 08035
        • Hospital Universitari Vall d'Hebron
    • Lleida [lérida]
      • Lleida, Lleida [lérida], Spanien, 25198
        • Hospital Universitario Arnau de Vilanova de Lleida
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spanien, 28041
        • Hospital Universitario 12 de Octubre

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histological or cytological diagnosis of breast cancer. At time of enrollment this must not be amenable to surgical resection with curative intent (≥1% ER+ stained cells as per local practice on the most recent tumor biopsy HER2- tumor by IHC or in-situ hybridization per ASCO/CAP).

  • prior anticancer therapies: Phase 1b: at least 1 line of SOC for A/MBC; Prior fulvestrant allowed; ≤1 prior chemotherapy line (no antibody-drug conjugates permitted) for A/MBC setting allowed. Phase 2: At least one and maximum 2 lines of ET in A/MBC setting and most recent ET-based regimen for >6 months.

    1, and only 1, prior CDK4/6 inhibitor-based regimen required. Up to 1 prior regimen of cytotoxic chemotherapy (no antibody-drug conjugates permitted) in the A/MBC setting; Prior fulvestrant allowed.

  • Participant with only non-measurable lesion (Phase1b) or at least 1 measurable lesion as defined by RECIST v1.1. (Phase2) are eligible.

  • ECOG PS = 0 or 1 (Phase1b) ; ≤2 (Phase2)

Exclusion Criteria:

  • visceral crisis at risk of life-threatening complications in the short term.
  • Any condition precluding an adeguate absorption of study interventions.
  • newly diagnosed brain metastases, or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 28 days prior to enrollment in the of study.
  • history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix. Inflammatory breast cancer are excluded
  • impaired cardiovascular function or clinically significant cardiovascular diseases.
  • concurrent administration of medications, food, or herb supplements that are strong inhibitors/inducers of CYP3A or UGT2B7, moderate inducers of CYP34 (Phase1b only) and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
  • renal impairment, not adequate liver function and/or bone marrow function.
  • known active infection

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: vepdegestrant in combination with PF-07220060

vepdegestrant administered orally once daily (QD) continuously and PF-07220060 administered orally twice daily (BID) continuously on 28-day cycles
Medicin: vepdegestrant

Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

Andre navne:
  • ARV-471 / PF07850327
Medicin: PF-07220060

Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1b
Tidsramme: Cycle 1 (28 days)

Hematological DLT: neutropenic fever; Grade>=3 thrombocytopenia associated with Grade>=2(clinically significant)bleeding and Grade4 neutropenia/thrombocytopenia lasting <7 days. Non-hematological: Grade>=3 toxicities clinically significant,except those that were not been maximally treated;Grade 2 aspartate aminotransferase(AST), alanine aminotransferase(ALT)/alkaline phosphatase(ALP) levels at baseline as result of liver/bone metastasis,AST,ALT and ALP level>8*baseline/AST/ALT >5*baseline for>=14 days; Hy's Law(concomitant ALT/AST elevation of >=3*upper limit of normal [ULN], total bilirubin elevation>=2*ULN without clear alternative etiology); Grade≥3 electrolyte abnormality with clinical sequelae; QTcF prolongation:any Grade>=3 QT prolongation without clear alternative etiology;any adverse event (AE) attributed to Vepdegestrant and/or PF-07220060 resulting in failure to deliver 75% of doses for either/both agents and any death not clearly due to underlying disease/extraneous causes.
Cycle 1 (28 days)
Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2
Tidsramme: From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)

OR was defined as best overall response (BOR) of confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis <10 millimeter [mm]). PR was defined as at least a >=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related TEAEs: Phase 1b
Tidsramme: From the date of first dose of study treatment combination through study completion

AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. Serious adverse event (SAE): any untoward medical occurrence, at any dose met one or more of following criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.
From the date of first dose of study treatment combination through study completion
Number of Participants With Laboratory Abnormalities: Phase 1b
Tidsramme: From the date of first dose of study treatment combination through study completion

Laboratory parameters assessed: hemoglobin, platelets, white blood cells (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR), uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.
From the date of first dose of study treatment combination through study completion
Number of Participants With Electrocardiogram (ECG) Abnormalities: Phase 1b
Tidsramme: From the date of first dose of study treatment combination through study completion

Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.
From the date of first dose of study treatment combination through study completion
Percentage of Participants With Confirmed OR by Derived Investigator Assessment: Phase 1b
Tidsramme: From the date of first dose of study treatment combination through study completion

OR was defined as BOR of confirmed CR or PR according to RECIST v 1.1. CR was defined as complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). PR was defined as at least a >=30% decrease from baseline in the sum of diameters of all target lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.
From the date of first dose of study treatment combination through study completion
Duration of Response (DOR) by Derived Investigator Assessment: Phase 1b
Tidsramme: From the date of first dose of study treatment combination through study completion

DoR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: >=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of >2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
From the date of first dose of study treatment combination through study completion
Clinical Benefit Response (CBR) by Derived Investigator Assessment: Phase 1b
Tidsramme: From the date of first dose of study treatment combination through study completion

CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) >=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis<10 mm). PR: at least >=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.
From the date of first dose of study treatment combination through study completion
Progression Free Survival (PFS) by Derived Investigator Assessment: Phase 1b
Tidsramme: From the date of first dose of study treatment combination through study completion

PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
From the date of first dose of study treatment combination through study completion
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Tidsramme: Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
Cycle 1, Day 8: Pre-dose; Cycle 1 Day 15: Pre-dose, 30 minutes, 1, 2, 4 ,6, 8 and 12 hours post-dose; Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Plasma Concentration of PF-07220060: Phase 1b
Tidsramme: Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
Pre-dose (0 hour) of Day 8 of Cycle 1; pre-dose (0 hour), 0.5,1,2,4,6,8 and 12 hours post-dose of Day 15 of Cycle 1; Pre-dose (0 hour) and anytime between 4 to 8 hour post-dose of Day 1 and 15 of Cycle 2; Pre-dose (0 hour) of Day 1 of Cycle 3, 5 and 7
Steady State Maximum Observed Plasma Concentration (Cmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

Cmax,ss was the steady-state maximum concentration of ARV-471 after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Cmax,ss of PF-07220060: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data. ARV-473 is an epimer of ARV-471. ARV-473 is an epimer of ARV-471.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Tmax,ss of PF-07220060: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

Tmax,ss was the steady-state time to maximum plasma concentration after multiple doses and was directly observed from data.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Steady State Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,ss) of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
AUClast,ss of PF-07220060: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

AUClast,ss was defined as area under the plasma concentration time curve from time zero to the last measurable concentration as steady state. AUClast,ss was calculated using linear/log trapezoidal method.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Apparent Total Clearance (CL/F) of Vepdegestrant (ARV-471): Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
CL/F of PF-07220060: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as dose administered divided by AUCinf. AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Apparent Volume of Distribution (Vz/F) of PF-07220060: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

Vz/F was calculated as Dose/(AUCinf * kel). AUCinf was calculated as AUClast + (Clast/kel), where, AUClast= area under the concentration-time curve from time 0 to time of last measurable concentration, Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
Terminal Half-Life (t1/2) of PF-07220060: Phase 1b
Tidsramme: Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15

T1/2 was calculated as loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Predose (0 hours), 0.5, 1, 2, 4, 6, 8, and 12 hours post dose on Cycle 1 Day 15
DOR by Derived Investigator Assessment: Phase 2
Tidsramme: From the date of first dose of study treatment combination through study completion

DOR: for participants with OR: time from first documentation of CR/PR to first documentation of PD/death. CR: complete disappearance of all target lesions (L), except nodal disease, complete disappearance of all non-target L and no new L. Both target and non-target nodes, must decrease to normal. PR: >=30% decrease from baseline in sum of diameters of target L. Short diameter used in sum for nodal target L, longest diameter used in sum for non-nodal target L. PD: 20% increase in sum of diameter of target measurable L above smallest sum observed, minimum absolute increase of 5 mm for target L/unequivocal progression of pre-existing L for non-target L. DOR censored on date of last adequate disease assessment for participants who did not have DOR event, discontinued study treatment due to withdrawal of consent prior to event, started new anticancer therapy prior to event, had event after gap of >2 missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
From the date of first dose of study treatment combination through study completion
Percentage of Participants With CBR by Derived Investigator Assessment: Phase 2
Tidsramme: From the date of first dose of study treatment combination through study completion

CBR was defined as percentage of participants with BOR of confirmed CR or PR at any time, or stable disease (SD) >=24 weeks as per RECIST v1.1. CR: complete disappearance of all target lesions, except for nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes, both target and non-target, must decrease to normal (short axis<10 mm). PR: at least >=30% decrease from baseline in sum of diameters of all target lesions. Short diameter was used in sum for nodal target lesions, while longest diameter was used in sum for non-nodal target lesions, all target lesions were assessed. SD: did not qualify for CR, PR, PD. All target lesions were assessed. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion.
From the date of first dose of study treatment combination through study completion
PFS by Derived Investigator Assessment: Phase 2
Tidsramme: From the date of first dose of study treatment combination through study completion

PFS was defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurred first as per RECIST v1.1. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, minimum absolute increase of 5mm for target lesions/unequivocal progression of pre-existing lesions for non-target lesion. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method will be used.
From the date of first dose of study treatment combination through study completion
Overall Survival (OS): Phase 2
Tidsramme: From the date of first dose of study treatment combination through study completion

OS was defined as the time from the date of first dose of study treatment combination to the date of death due to any cause. Participants last known to be alive were censored at the date of last contact. Kaplan-Meier method will be used.
From the date of first dose of study treatment combination through study completion
Number of Participants With TEAEs, TESAEs and Treatment Related TEAEs: Phase 2
Tidsramme: From the date of first dose of study treatment combination through study completion

AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. AEs includes both SAEs and all other AEs (non-SAEs). TEAEs will be those events with onset dates occurring during the on-treatment period. Relatedness to study drug judged by investigator.
From the date of first dose of study treatment combination through study completion
Number of Participants With ECG Abnormalities: Phase 2
Tidsramme: From the date of first dose of study treatment combination through study completion

Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes.
From the date of first dose of study treatment combination through study completion
Number of Participants With Laboratory Abnormalities: Phase 2
Tidsramme: From the date of first dose of study treatment combination through study completion

Laboratory parameters assessed included hemoglobin, platelets, WBC, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils, ALT, AST, ALP, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, urea or BUN, creatinine, eGFR, uric acid, glucose (fasted), albumin, phosphorus, lipase and amylase.
From the date of first dose of study treatment combination through study completion
Plasma Concentration of Vepdegestrant (ARV-471) and Its Epimer ARV-473: Phase 2
Tidsramme: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hour post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Plasma Concentration of PF-07220060: Phase 2
Tidsramme: Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.
Cycle 1, Day 15 and Cycle 2 Days 1 and 15: Pre-dose, anytime between 4 to 8 hours post-dose; Cycles 3, 5, and 7, Day 1: Pre-dose
Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Plasma Level: Phase 2
Tidsramme: Baseline and up to End of Treatment
Baseline and up to End of Treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Pfizer

Samarbejdspartnere

Arvinas Estrogen Receptor, Inc.

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. februar 2024

Primær færdiggørelse (Faktiske)

5. september 2025

Studieafslutning (Anslået)

25. maj 2027

Datoer for studieregistrering

Først indsendt

13. december 2023

Først indsendt, der opfyldte QC-kriterier

4. januar 2024

Først opslået (Faktiske)

16. januar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • C4891026
  • 2023-508130-33-00 (Registry Identifier: CTIS (EU))
  • TACTIVE-K (Anden identifikator: Alias Study Number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner